Clostridium Difficile Infection
Conquering C. Difficile Associated Diarrhea with Probiotics
According to a recent study published by the Cochrane Library, the administration of probiotics to those at high-risk of developing C.difficile-associated diarrhea (CDAD) reduced a patient’s risk by 70%. This finding provides a low-cost, non-invasive option for reducing incidences of CDAD and the associated patient suffering. But the effectiveness of the treatment requires the early identification of at-risk patients who could benefit from probiotics. This is where the Jvion Machine is bridging the gap between new treatments and at-risk populations.
The patient population at high-risk of developing CDAD comprises 15% of the total patient population. These individuals are at more than 10% risk of developing the infection with an overall incidence rate of 1.7%.
The Jvion Machine is able to correctly identify 95% of all CDAD cases in the 15% of the population where the risk is greater than 10%. For a medium-size hospital with a patient population of 20,000, 3,000 patients would be at high-risk, and of those 323 would develop CDAD. If probiotics are administered to the high-risk population, it stands to reason that 226 or (70%) of these incidences could be prevented.
Probiotics cost $24 per patient. Using the Jvion Machine, we can target the administration of these probiotics to the 15% of the population at high-risk of an infection. The total spend of the intervention across all 3,000 patients comes to $72,000. The cost estimate per CDAD episode cited within the Cochrane study is $7,286. By preventing the anticipated 226 cases of CDAD, we would avoid $1,646,636 in costs. The total cost savings after accounting for the cost of treatment is $1,574,636. And this is all enabled by the ability to identify who is on a trajectory toward CDAD risk, providing the right information on the contributors to that risk, and enabling the clinical action that will lead to the best possible outcomes—in this case probiotics.